Clinical Trial Details
— Status: Not yet recruiting
Administrative data
| NCT number |
NCT05514951 |
| Other study ID # |
2022-A00787-36 |
| Secondary ID |
|
| Status |
Not yet recruiting |
| Phase |
N/A
|
| First received |
|
| Last updated |
|
| Start date |
November 15, 2022 |
| Est. completion date |
November 30, 2022 |
Study information
| Verified date |
November 2022 |
| Source |
Vifor Pharma |
| Contact |
Serge MAILLET |
| Phone |
+ 33 1 80 04 16 39 |
| Email |
serge.maillet[@]viforpharma.com |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
Iron deficiency is defined by insufficient tissue iron stores and anemia is the ultimate
stage of iron deficiency. Anemia should never be neglected in an elderly subject because it
is associated with an increase in mortality, but also with a increased morbidity in terms of
complications
Apart from anemia, iron deficiency is common and constitutes a factor of poor prognosis in
diseases chronic, all pathologies very frequently found in the elderly. It is the origin of
the deterioration in the general condition of patients, their re-hospitalization or even the
progression of their pathology.
In this context where elderly patients also present a certain number of comorbidities
including the pathologies mentioned previously, it is important to better diagnose the
deficiency martial in the elderly patient.
Description:
Iron deficiency (MD) is defined by insufficient tissue iron stores. Since iron is essential
for the synthesis of hemoglobin, when the iron deficiency no longer makes it possible to
maintain a sufficient level of erythropoiesis, anemia appears: it is the ultimate stage of
iron deficiency.
Anemia is the most common haematological pathology encountered in geriatric practice. Its
prevalence, in population generally ambulatory, is between 10 and 15% after the age of 65 and
is greater than 20% beyond the age of 85.
Anemia should never be neglected in an elderly subject because it is associated with an
increase in mortality, but also with a increased morbidity in terms of complications heart
disease, cognitive decline, frailty, hospitalizations, and impairment of quality of life.
About a third of anemias elderly person is attributable to a deficiency in vitamin B9 or B12
or an iron deficiency.
Apart from anemia, iron deficiency is common and constitutes a factor of poor prognosis in
diseases chronic such as heart failure, kidney failure chronic or cancer, all pathologies
very frequently found in the elderly. It is the origin of the deterioration in the general
condition of patients, their re-hospitalization or even the progression of their pathology.
In this context where elderly patients also present a certain number of comorbidities
including the pathologies mentioned previously, it is important to better diagnose the
deficiency martial in the elderly patient.
This diagnosis is all the more important because, depending on the chronic pathology, data
from the literature have shown that correcting the iron deficiency brings benefits to the
patient by reducing the risk of recurrence of anemia, the prescription of erythropoietin and
the use of transfusion for patients in oncology, gastroenterology and nephrology
